查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1742514

糖尿病前症的全球市場:各產品類型，各年齡層，各終端用戶，各地區，機會，預測，2018年～2032年

Prediabetes Market Assessment, By Product Type, By Age Group, By End-user, By Region, Opportunities and Forecast, 2018-2032F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 264 Pages | 商品交期: 3-5個工作天內

價格

全球糖尿病前期市場規模預計將從2024年的3.3054億美元增長至2032年的6.6129億美元，在2025-2032年的預測期內，複合年增長率為9.06%。由於肥胖率上升、遺傳因素、人口老化加劇以及加工食品和含糖食品及飲料消費量增加，糖尿病前期發病率呈上升趨勢。根據國際糖尿病聯盟的估計，到2050年，將有8.53億成年人罹患糖尿病。

隨著一般民眾和醫療保健專業人員對早期發現糖尿病以及採取乾預措施以防止其發展為2型糖尿病重要性的認識不斷提高，市場需求也隨之增長。人口增長也催生了對糖尿病前期相關產品和服務的巨大需求。肥胖、不健康飲食和久坐不動的生活方式日益增多，進一步增加了糖尿病的風險。因此，市場領導者正致力於推出持續血糖監測的新產品。例如，雅培實驗室於2024年9月推出了Lingo，這是一款非處方 (OTC) 持續血糖監測儀 (CGM)，適用於不服用胰島素但希望改善健康的成年人。

本報告提供全球糖尿病前症市場相關調查，提供市場概要，以及各產品類型，各年齡層，各終端用戶，各地區趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 計劃的範圍和定義

第2章 調查手法

第3章 美國的關稅的影響

第4章 摘要整理

第5章 全球糖尿病前症市場預測，2018年～2032年

  • 市場規模分析與預測
  • 市場佔有率分析與預測
    • 各產品類型
      • 診斷及設備
      • 醫藥品及治療藥
      • 營養補充品和機能性食品
      • 其他
    • 各年齡層
      • 兒童
      • 大人
      • 老年人
    • 各終端用戶
      • 醫院和診療所
      • 診斷中心
      • 居家照護
      • 其他
    • 各地區
      • 北美
      • 歐洲
      • 亞太地區
      • 南美
      • 中東·非洲
    • 各企業市場佔有率分析(前五名公司以及其他- 各金額，2024年)
  • 2024年的市場地圖分析

第6章 北美的糖尿病前症市場預測，2018年～2032年

  • 市場規模分析與預測
  • 市場佔有率分析與預測
  • 各國市場評估
    • 美國
    • 加拿大
    • 墨西哥

第7章 歐洲的糖尿病前症市場預測，2018年～2032年

  • 德國
  • 法國
  • 義大利
  • 英國
  • 俄羅斯
  • 荷蘭
  • 西班牙
  • 土耳其
  • 波蘭

第8章 亞太地區的糖尿病前症市場預測，2018年～2032年

  • 印度
  • 中國
  • 日本
  • 澳洲
  • 越南
  • 韓國
  • 印尼
  • 菲律賓

第9章 南美的糖尿病前症市場預測，2018年～2032年

  • 巴西
  • 阿根廷

第10章 中東·非洲的糖尿病前症市場預測，2018年～2032年

  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第11章 需求供給分析

第12章 價值鏈分析

第13章 波特的五力分析

第14章 大環境分析

第15章 價格分析

第16章 市場動態

  • 市場促進因素
  • 市場課題

第17章 市場趨勢與發展

  • 與產品的銷售核准
  • 創新
  • 臨床試驗

第18章 政策和法規情形

第19章 案例研究

第20章 競爭情形

  • 前五名市場領導的競爭矩陣
  • 前五名參與企業的SWOT分析
  • 前10名市場主要企業的形勢
    • Abbott Laboratories
    • F. Hoffmann-La Roche Ltd.
    • Siemens Healthineers AG
    • Ascensia Diabetes Care Holdings AG
    • Omada Health, Inc.
    • Noom, Inc.
    • Eli Lilly and Company
    • PharmaLinea nutraceuticals, Ltd.
    • Oramed Pharmaceuticals Inc.
    • Bayer AG

第21章 策略性建議

第22章 關於調查公司·免責聲明

Product Code: MX13260

Global prediabetes market is projected to witness a CAGR of 9.06% during the forecast period 2025-2032, growing from USD 330.54 million in 2024 to USD 661.29 million in 2032. Prediabetes cases are increasing due to rise of obesity, genetics factors, expansion of the aging population and increasing consumption of processed foods and sugar rich beverages. As per the estimate of the International Diabetes Federation, 853 million adults will have diabetes by 2050.

Increasing awareness among the general population and healthcare professionals about the importance of early detection of the condition and intervention to prevent the progression to type 2 diabetes is further propelling the market's demand. The rising population increases the demand of prediabetes-related products and services tremendously. Increasing obesity, unhealthy diet, and sedentary lifestyle are further increasing the risk of diabetes. Thus, leading market players are focusing on launching new products continuous glucose monitoring. For instance, in September 2024, Abbott Laboratories, launched Lingo, an over-the-counter (OTC) continuous glucose monitor (CGM) for adults that do not take insulin and want to improve their health.

Technological Advancement Supports Market Expansion

Technological advancements are driving the growth of the prediabetes market by enhancing diagnostic and monitoring capabilities, such as continuous glucose monitoring systems and digital health solutions. It also provides accurate and personalized treatment approaches by adding artificial intelligence (AI) and machine learning tools for quick results and provide relief for both patient and the healthcare provider. These innovations facilitate better management and awareness of prediabetes, addressing the rising incidence of lifestyle-related disease. Innovations in CGM systems, smartphone apps, portable glucometers and AI detection tools enhance the early detection of glucose irregularities and prevention from Type 2 diabetes. Almost half of all adults with diabetes are not aware that they are suffering from it, thus, leading players in the market are focusing on launching advanced diabetes detection tools. For instance, in November 2024, Redcliffe labs launched a digital diabetes risk checker tool on its official android app.

Increasing Research Activities Support Market Expansion

Ongoing clinical trials and research studies are expanding the understanding of prediabetes and allowing researchers to develop new therapies such as GLP-1 receptor agonists and combination therapies, which show promise in improving glycemic control and reducing associated risks. Research into biomarkers and advanced technologies like CGM are improving diagnostic precision and patient management. Various research institutions are focusing on developing programs that allow patients to reverse their prediabetes with lifestyle changes. For instance, in December 2024, a new program was launched in the St. John's region in Canada to assist individuals in reversing their progression toward type 2 diabetes. The four-week program is available across different YMCAs across Canada and is expected to aid patients in reversing their prediabetes with dietary changes and exercise.

Adults Hold Major Market Share

As per the age group adults have more diabetes due to the unhealthy lifestyle, obesity, genetics factors and lack of more consumption of fresh food products. As per the estimates of the International Diabetes Federation, in 2024, approximately 589 million adults were living with diabetes.

Individuals in this age group are more inclined to participate in regular health screenings, workplace wellness initiatives, and digital health monitoring, which contribute to the early identification and diagnosis of prediabetes. As healthcare professionals increasingly prioritize prevention and long-term health results, there is a heightened focus on early intervention, especially among younger individuals, to postpone or avert the development of type 2 diabetes. The rising use of fitness trackers, health applications, and telehealth services among adults aged 18-49 has also facilitated proactive health monitoring and lifestyle management, promoting early diagnosis and involvement in preventive healthcare.

North America Dominates the Prediabetes Market

North America is exerting its dominance in the prediabetes market due to a combination of high prevalence rates, advanced healthcare systems and effective public health strategies. In North America millions of adults are affected by prediabetes, creating significant demand for screening, diagnosis and treatment options. They enjoy robust healthcare infrastructures that facilitate early detection, preventive services, and insurance support. Initiatives such as the CDC's National Diabetes Prevention Programs (NDPP), along with considerable funding and public awareness efforts, further enhance market's expansion. Furthermore, North America is at the forefront of digital health innovation, evidenced by the extensive adoption of remote monitoring technologies, AI-powered applications, and interconnected devices deployed by companies such as Omada Health Inc. and Livongo (Teladoc Health, Inc.) are allowing for easy management of diabetes. Investment from the private sector in diabetes prevention and management technology also bolsters the region's prominence in this field.

Leading players in the reasons are focusing on launching new products and technology to reduce the burden of diabetes. For instance, March 2025 Tandem Diabetes Care, Inc. introduced its upgraded Control-IQ+ automated insulin delivery system in the United States.

Impact of U.S. Tariffs on Global Prediabetes Market

The tariffs imposed by the U.S. have introduced significant challenges for the prediabetes market and are expected to affect the accessibility and affordability of essential diagnostic and blood glucose monitoring tools that are essential in diabetes management. Additionally, tariffs are disrupting supply chains, leading to delays or shortages in the distribution of these products.

In response to the tariffs, leading pharmaceutical companies are investing in expanding their manufacturing base in the United States to reduce their reliance on imports. However, changes in manufacturing locations can trigger additional compliance requirements, resulting in delays in the introduction of new products and technologies.

Key Players Landscape and Outlook

Continuous innovation characterizes the landscape of prediabetes market globally, the market is driven by escalating prevalence of prediabetes and strong preference for preventive healthcare. To maintain their position in the market the key players are investing in innovation and research activities as well as nutraceuticals and functional foods. They collaborate with academic institutes and partner with pharmaceutical companies, tech firms and health care providers to integrate care modals.

For instance, in August 2024, Eli Lilly and Company announced favorable initial findings from the SURMOUNT-1 three-year trial assessing the effectiveness and safety of tirzepatide administered once a week for long-term weight management and delaying the onset of diabetes in adults with pre-diabetes and obesity or overweight.

Similarly, in March 2023, Pharma Linea Nutraceuticals Ltd launched Prediabetiq capsule to provide immediate improvements in glycemic response that can be easily measured in real-time.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Global Prediabetes Market Outlook, 2018-2032F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Product Type
      • 5.2.1.1. Diagnostics and Devices
        • 5.2.1.1.1. Blood Glucose Monitoring Devices
        • 5.2.1.1.2. Point-of-Care Testing (POCT) Devices
        • 5.2.1.1.3. Testing Kits
        • 5.2.1.1.4. Others
      • 5.2.1.2. Pharmaceuticals and Therapeutics
        • 5.2.1.2.1. Metformin and Oral Antidiabetics (OADs)
        • 5.2.1.2.2. Insulin Sensitizers
        • 5.2.1.2.3. Others
      • 5.2.1.3. Nutraceuticals and Functional Foods
        • 5.2.1.3.1. Blood Sugar Control Supplements
        • 5.2.1.3.2. Weight Management Supplements
        • 5.2.1.3.3. Others
      • 5.2.1.4. Others
    • 5.2.2. By Age Group
      • 5.2.2.1. Children
      • 5.2.2.2. Adults
      • 5.2.2.3. Elderly
    • 5.2.3. By End-user
      • 5.2.3.1. Hospitals and Clinics
      • 5.2.3.2. Diagnostic Centers
      • 5.2.3.3. Homecare Settings
      • 5.2.3.4. Others
    • 5.2.4. By Region
      • 5.2.4.1. North America
      • 5.2.4.2. Europe
      • 5.2.4.3. Asia-Pacific
      • 5.2.4.4. South America
      • 5.2.4.5. Middle East and Africa
    • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 5.3. Market Map Analysis, 2024
    • 5.3.1. By Product Type
    • 5.3.2. By Age Group
    • 5.3.3. By End-user
    • 5.3.4. By Region

6. North America Prediabetes Market Outlook, 2018-2032F

  • 6.1. Market Size Analysis & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share Analysis & Forecast
    • 6.2.1. By Product Type
      • 6.2.1.1. Diagnostics and Devices
        • 6.2.1.1.1. Blood Glucose Monitoring Devices
        • 6.2.1.1.2. Point-of-Care Testing (POCT) Devices
        • 6.2.1.1.3. Testing Kits
        • 6.2.1.1.4. Others
      • 6.2.1.2. Pharmaceuticals and Therapeutics
        • 6.2.1.2.1. Metformin and Oral Antidiabetics (OADs)
        • 6.2.1.2.2. Insulin Sensitizers
        • 6.2.1.2.3. Others
      • 6.2.1.3. Nutraceuticals and Functional Foods
        • 6.2.1.3.1. Blood Sugar Control Supplements
        • 6.2.1.3.2. Weight Management Supplements
        • 6.2.1.3.3. Others
      • 6.2.1.4. Others
    • 6.2.2. By Age Group
      • 6.2.2.1. Children
      • 6.2.2.2. Adults
      • 6.2.2.3. Elderly
    • 6.2.3. By End-user
      • 6.2.3.1. Hospitals and Clinics
      • 6.2.3.2. Diagnostic Centers
      • 6.2.3.3. Homecare Settings
      • 6.2.3.4. Others
    • 6.2.4. By Country Share
      • 6.2.4.1. United States
      • 6.2.4.2. Canada
      • 6.2.4.3. Mexico
  • 6.3. Country Market Assessment
    • 6.3.1. United States Prediabetes Market Outlook, 2018-2032F*
      • 6.3.1.1. Market Size Analysis & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share Analysis & Forecast
    • 6.3.2. By Product Type
      • 6.3.2.1. Diagnostics & Devices
        • 6.3.2.1.1. Blood Glucose Monitoring Devices
        • 6.3.2.1.2. Point-of-Care Testing (POCT) Devices
        • 6.3.2.1.3. Testing Kits
        • 6.3.2.1.4. Others
      • 6.3.2.2. Pharmaceuticals and Therapeutics
        • 6.3.2.2.1. Metformin and Oral Antidiabetics (OADs)
        • 6.3.2.2.2. Insulin Sensitizers
        • 6.3.2.2.3. Others
      • 6.3.2.3. Nutraceuticals and Functional Foods
        • 6.3.2.3.1. Blood Sugar Control Supplements
        • 6.3.2.3.2. Weight Management Supplements
        • 6.3.2.3.3. Others
      • 6.3.2.4. Others
    • 6.3.3. By Age Group
      • 6.3.3.1. Children
      • 6.3.3.2. Adults
      • 6.3.3.3. Elderly
    • 6.3.4. By End-user
      • 6.3.4.1. Hospitals and Clinics
      • 6.3.4.2. Diagnostic Centers
      • 6.3.4.3. Homecare Settings
      • 6.3.4.4. Others
    • 6.3.5. Canada
    • 6.3.6. Mexico

All segments will be provided for all regions and countries covered

7. Europe Prediabetes Market Outlook, 2018-2032F

  • 7.1. Germany
  • 7.2. France
  • 7.3. Italy
  • 7.4. United Kingdom
  • 7.5. Russia
  • 7.6. Netherlands
  • 7.7. Spain
  • 7.8. Turkey
  • 7.9. Poland

8. Asia-Pacific Prediabetes Market Outlook, 2018-2032F

  • 8.1. India
  • 8.2. China
  • 8.3. Japan
  • 8.4. Australia
  • 8.5. Vietnam
  • 8.6. South Korea
  • 8.7. Indonesia
  • 8.8. Philippines

9. South America Prediabetes Market Outlook, 2018-2032F

  • 9.1. Brazil
  • 9.2. Argentina

10. Middle East and Africa Prediabetes Market Outlook, 2018-2032F

  • 10.1. Saudi Arabia
  • 10.2. UAE
  • 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

  • 17.1. Product Launches and Approvals
  • 17.2. Innovation
  • 17.3. Clinical Trials

18. Policy and Regulatory Landscape

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. Abbott Laboratories
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 20.3.2. F. Hoffmann-La Roche Ltd.
    • 20.3.3. Siemens Healthineers AG
    • 20.3.4. Ascensia Diabetes Care Holdings AG
    • 20.3.5. Omada Health, Inc.
    • 20.3.6. Noom, Inc.
    • 20.3.7. Eli Lilly and Company
    • 20.3.8. PharmaLinea nutraceuticals, Ltd.
    • 20.3.9. Oramed Pharmaceuticals Inc.
    • 20.3.10. Bayer AG

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 2. Global Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 3. Global Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 4. Global Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 5. Global Prediabetes Market Share (%), By Region, 2018-2032F
  • Figure 6. North America Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 7. North America Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 8. North America Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 9. North America Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 10. North America Prediabetes Market Share (%), By Country, 2018-2032F
  • Figure 11. United States Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 12. United States Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 13. United States Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 14. United States Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 15. Canada Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 16. Canada Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 17. Canada Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 18. Canada Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 19. Mexico Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 20. Mexico Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 21. Mexico Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 22. Mexico Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 23. Europe Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 24. Europe Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 25. Europe Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 26. Europe Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 27. Europe Prediabetes Market Share (%), By Country, 2018-2032F
  • Figure 28. Germany Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 29. Germany Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 30. Germany Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 31. Germany Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 32. France Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 33. France Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 34. France Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 35. France Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 36. Italy Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 37. Italy Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 38. Italy Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 39. Italy Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 40. United Kingdom Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 41. United Kingdom Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 42. United Kingdom Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 43. United Kingdom Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 44. Russia Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 45. Russia Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 46. Russia Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 47. Russia Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 48. Netherlands Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 49. Netherlands Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 50. Netherlands Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 51. Netherlands Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 52. Spain Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 53. Spain Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 54. Spain Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 55. Spain Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 56. Turkey Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 57. Turkey Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 58. Turkey Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 59. Turkey Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 60. Poland Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 61. Poland Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 62. Poland Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 63. Poland Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 64. South America Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 65. South America Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 66. South America Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 67. South America Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 68. South America Prediabetes Market Share (%), By Country, 2018-2032F
  • Figure 69. Brazil Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 70. Brazil Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 71. Brazil Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 72. Brazil Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 73. Argentina Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 74. Argentina Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 75. Argentina Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 76. Argentina Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 77. Asia-Pacific Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 78. Asia-Pacific Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 79. Asia-Pacific Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 80. Asia-Pacific Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 81. Asia-Pacific Prediabetes Market Share (%), By Country, 2018-2032F
  • Figure 82. India Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 83. India Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 84. India Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 85. India Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 86. China Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 87. China Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 88. China Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 89. China Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 90. Japan Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 91. Japan Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 92. Japan Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 93. Japan Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 94. Australia Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 95. Australia Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 96. Australia Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 97. Australia Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 98. Vietnam Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 99. Vietnam Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 100. Vietnam Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 101. Vietnam Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 102. South Korea Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 103. South Korea Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 104. South Korea Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 105. South Korea Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 106. Indonesia Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 107. Indonesia Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 108. Indonesia Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 109. Indonesia Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 110. Philippines Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 111. Philippines Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 112. Philippines Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 113. Philippines Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 114. Middle East & Africa Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 115. Middle East & Africa Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 116. Middle East & Africa Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 117. Middle East & Africa Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 118. Middle East & Africa Prediabetes Market Share (%), By Country, 2018-2032F
  • Figure 119. Saudi Arabia Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 120. Saudi Arabia Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 121. Saudi Arabia Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 122. Saudi Arabia Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 123. UAE Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 124. UAE Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 125. UAE Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 126. UAE Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 127. South Africa Prediabetes Market, By Value, In USD Million, 2018-2032F
  • Figure 128. South Africa Prediabetes Market Share (%), By Product Type, 2018-2032F
  • Figure 129. South Africa Prediabetes Market Share (%), By Age Group, 2018-2032F
  • Figure 130. South Africa Prediabetes Market Share (%), By End-user, 2018-2032F
  • Figure 131. By Product Type Map-Market Size (USD Million) & Growth Rate (%), 2024
  • Figure 132. By Age Group Map-Market Size (USD Million) & Growth Rate (%), 2024
  • Figure 133. By End-user Map-Market Size (USD Million) & Growth Rate (%), 2024
  • Figure 134. By Region Map-Market Size (USD Million) & Growth Rate (%), 2024